scroll to top
0

EBSCO Auth Banner

Let's find your institution. Click here.

Advanced Search Results For "Patents as Topic"

1 - 10 of 11,038 results for
 "Patents as Topic"
Results per page:

A patent review of pharmaceutical and therapeutic applications of oxadiazole derivatives for the treatment of chronic diseases (2013-2021).

Publication Type: Academic Journal

Source(s): Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2022 Sep; Vol. 32 (9), pp. 969-1001. Date of Electronic Publication: 2022 Sep 06.

Abstract: Introduction: Oxadiazole is a unique class of heterocycle, possessing numerous important biomedical and therapeutic applications, such as anti-bacterial, anti-cancer, anti-inflammatory, inhibitors for diverse enzymes, receptor modulators, and neuroprot...

View details

Inhibitors of protease-activated receptor 4 (PAR4): a review of recent patents (2013-2021).

Publication Type: Academic Journal

Source(s): Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2022 Feb; Vol. 32 (2), pp. 153-170. Date of Electronic Publication: 2022 Feb 16.

Authors:

Abstract: Introduction: Protease-activated receptor 4 (PAR4), belonging to a subfamily of G-protein-coupled receptors (GPCR), is expressed on the surface of Human platelets, and the activation of it can lead to platelets aggregation. Studies demonstrated that PA...

View details

A patent review of ubiquitin-specific protease 7 (USP7) inhibitors (2014-present).

Publication Type: Academic Journal

Source(s): Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2022 Jul; Vol. 32 (7), pp. 753-767. Date of Electronic Publication: 2022 Mar 31.

Authors:

Abstract: Introduction: Ubiquitin-specific protease 7 (USP7) plays a critical role in multiple signaling pathways, and many recent studies have proved its association with many diseases. The USP7-murine double minute 2-p53 pathway and the relationship between US...

View details

An updated patent review on monoamine oxidase (MAO) inhibitors.

Publication Type: Academic Journal

Source(s): Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2022 Aug; Vol. 32 (8), pp. 849-883. Date of Electronic Publication: 2022 Jun 09.

Abstract: Introduction: Monoamine oxidase (MAO) inhibitors are currently used as antidepressants (selective MAO-A inhibitors) or as co-adjuvants for neurodegenerative diseases (selective MAO-B inhibitors). The research within this field is attracting attention d...

View details

Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).

Publication Type: Academic Journal

Source(s): Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2022 Aug; Vol. 32 (8), pp. 899-912. Date of Electronic Publication: 2022 Jul 05.

Abstract: Introduction: The Hippo pathway represents a new opportunity for the treatment of cancer. Overexpression of Yes-associated protein (YAP) or transcriptional coactivator with PDZ-binding motif (TAZ) or TEAD has been demonstrated in cancers and YAP mediat...

View details

Patents benefit patients and patent reform would spur diagnostic and therapeutic development.

Publication Type: Academic Journal

Source(s): Nature biotechnology [Nat Biotechnol] 2022 Aug; Vol. 40 (8), pp. 1178-1180.

Authors:
View details

Nucleotide pyrophosphatase/phosphodiesterases (NPPs) including NPP1 and NPP2/ ATX as important drug targets: A patent review (2015-2020).

Publication Type: Academic Journal

Source(s): Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2022 Jul; Vol. 32 (7), pp. 743-751. Date of Electronic Publication: 2022 Apr 12.

Abstract: Introduction: Ectobucleotidases are a broad class of extracellular nucleotide and nucleoside hydrolyzing enzymes. Since they play a crucial role in mediating purinergic cell signalling, they are promising therapeutic targets for treatment of a range of...

View details

ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective.

Publication Type: Academic Journal

Source(s): Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2022 Jul; Vol. 32 (7), pp. 731-742. Date of Electronic Publication: 2022 Apr 25.

Authors:

Abstract: Introduction: ATP citrate lyase (ACLY) is a key enzyme in cellular metabolism, being the main source of acetyl-Coenzyme A, an important precursor for fatty acid, cholesterol, and isoprenoid biosynthesis, and it is also involved in protein acetylation. ...

View details

Carbon-11 patents (2012-2022): synthetic methodologies and novel radiotracers for PET imaging.

Publication Type: Academic Journal

Source(s): Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2022 Jul; Vol. 32 (7), pp. 817-831. Date of Electronic Publication: 2022 Apr 28.

Abstract: Introduction: Carbon-11 is a short-lived radionuclide with versatile applications in synthetic methodologies to develop a variety of novel PET radiotracers. Different primary and secondary carbon-11 precursors are generated from cyclotron produced [ 11...

View details

P2X receptor antagonists and their potential as therapeutics: a patent review (2010-2021).

Publication Type: Academic Journal

Source(s): Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2022 Jul; Vol. 32 (7), pp. 769-790. Date of Electronic Publication: 2022 May 11.

Abstract: Introduction: Purinergic receptors play a critical role in neurotransmission, and modulation of complex physiological functions and thus have implications in numerous disease states. The past decade has seen substantial progress in the design of novel ...

View details
sponsored